Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts. Show more

101 Seaport Blvd., Boston, MA, 02210-2186, United States

https://www.seaporttx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.129B

52 Wk Range

$14.85 - $23.00

Previous Close

$21.94

Open

$22.06

Volume

53,550

Day Range

$20.98 - $22.16

Enterprise Value

952.2M

Cash

182.6M

Avg Qtr Burn

-20.17M

Insider Ownership

35.06%

Institutional Own.

35.44%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GlyphAllo/Glyph Allopregnanolone (SPT-300) (Neuroactive Steroid) Details Major Depressive Disorder	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAgo/Agomelatine (SPT-320) (Oral Prodrug) Details Generalized Anxiety Disorder	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAgo/Agomelatine (SPT-320) (Melatonergic Agonist) Details Generalized Anxiety Disorder	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAgo/Agomelatine (SPT-320) (Oral Prodrug) Details Generalized Anxiety Disorder With Sleep Disturbance	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAllo/Glyph Allopregnanolone (SPT-300) (Neuroactive Steroid) Details Driving Safety In Healthy Volunteers	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.